Loading
Every dated change on the records linked to Head and neck squamous cell carcinoma, newest first: approvals and regulatory steps on its medicines, trials that reported, guideline versions, milestones, and when this page itself was checked. Dates come from the records; none is inferred. Orientation, not medical advice.
Median EFS 59.
Three-year disease-free survival 63.
HN005: de-escalated arms had worse PFS; control 2-year PFS 98%.
Severe oral mucositis incidence 54% vs 64% (relative risk 0.
A milestone in how this cancer is treated.
A milestone in how this cancer is treated.
Median progression-free survival 9.
PFS HR 0.
TPEx did not improve overall survival over EXTREME, but gave similar survival with a shorter schedule and less toxicity.
A milestone in how this cancer is treated.
Unresectable locally advanced or recurrent head and neck cancer (conditional)
PFS HR 1.
Median OS 7.
A milestone in how this cancer is treated.
Head and neck squamous cell carcinoma (CPS ≥1) and oesophageal squamous cell carcinoma (CPS ≥10)
Severe toxicity similar; 2-year overall survival 97.
OS 14.
5-year overall survival 84.
A milestone in how this cancer is treated.
A milestone in how this cancer is treated.
OS 7.
A milestone in how this cancer is treated.
A milestone in how this cancer is treated.
Head and neck squamous cell carcinoma with radiation
Median overall survival 49.
First targeted agent in HNSCC.
A milestone in how this cancer is treated.